Filing Details

Accession Number:
0000899243-19-004398
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-21 16:54:37
Reporting Period:
2019-02-19
Accepted Time:
2019-02-21 16:54:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750019 Tcr2 Therapeutics Inc. TCRR () F4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1447960 China Molybdenum Co., Ltd. North Yihe, Huamei Shan Road
Luanchuan, Luoyang, Henan F4 471500
No No Yes No
1766474 Ltd Investment Upnorth Vistra Corporate Services Centre
Wickham'S Cay Ii
Road Town D8 VG1110
No No Yes No
1767622 China Molybdenum (Hong Kong) Co Ltd 21/F., Central 88
No. 88 Des Voeux Road Central
Hong Kong K3
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-19 322,902 $0.00 322,902 No 4 C Indirect By Upnorth Investment Limited
Common Stock Acquisiton 2019-02-19 1,614,517 $0.00 1,937,419 No 4 C Indirect By Upnorth Investment Limited
Common Stock Acquisiton 2019-02-19 200,000 $15.00 2,137,419 No 4 P Indirect By Upnorth Investment Limited
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Upnorth Investment Limited
No 4 C Indirect By Upnorth Investment Limited
No 4 P Indirect By Upnorth Investment Limited
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2019-02-19 2,000,000 $0.00 322,902 $0.00
Common Stock Series B Preferred Stock Disposition 2019-02-19 10,000,000 $0.00 1,614,517 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
  2. The reported securities are owned directly by Upnorth Investment Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
  3. Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.